A Macroprudential Perspective on the Regulatory Boundaries of US Financial Assets

This paper uses data from the Financial Accounts of the United States to map out the regulatory boundaries of assets held by US financial institutions from a macroprudential perspective. We provide a quantitative measure of the macroprudential regulatory boundary—the perimeter between the part of the financial sector that is subject to some form of macroprudential regulatory oversight and that which is not—and show how it has evolved over the past 40 years. Additionally, we measure the boundaries between different regulatory agencies and financial institutions that operate within the regulatory perimeter and illustrate how these boundaries potentially become blurred in the face of regulatory overlap. Quantifying the macroprudential regulatory boundary and the boundaries for different regulators within the perimeter is informative for assessing financial stability risks over the credit cycle

Driving Design Factors for Safe, High Power Batteries for Space Applications

Final Document is attached. New design features and test methods are in development at NASA to take advantage of the newest high power and energy dense commercial Li-ion cell designs and to achieve passively thermal runaway (TR) propagation resistant (PPR) designs for manned missions requiring high power/voltage. The goal is to minimize the parasitic mass and volume of the battery components; thus reaching a balance between high battery specific power (W/kg) and energy (Wh/kg) as well as power (W/L) and energy density (Wh/L). Current 18650 cell designs achieve greater than 275 Wh/kg, greater than 725 Wh/L, but present high risks of side wall breaching during TR which can defeat many other safety features resulting in nearly immediate TR propagation. This work seeks to better understand the phenomena of cell side wall breaches and to determine the effectiveness of promising battery design features for achieving safe, high performing battery designs for high voltage/power applications

A genome sequencing program for novel undiagnosed diseases

PURPOSE: The Scripps Idiopathic Diseases of huMan (IDIOM) study aims to discover novel gene-disease relationships and provide molecular genetic diagnosis and treatment guidance for individuals with novel diseases using genome sequencing integrated with clinical assessment and multidisciplinary case review. METHODS: Here we describe the IDIOM study operational protocol and initial results. RESULTS: 121 cases underwent first tier review by the principal investigators to determine if the primary inclusion criteria were satisfied, 59 (48.8%) underwent second tier review by our clinician-scientist review panel, and 17 (14.0%) patients and their family members were enrolled. 60% of cases resulted in a plausible molecular diagnosis. 18% of cases resulted in a confirmed molecular diagnosis. 2 of 3 confirmed cases led to the identification of novel gene-disease relationships. In the third confirmed case, a previously described but unrecognized disease was revealed. In all three confirmed cases, a new clinical management strategy was initiated based on the genetic findings. CONCLUSIONS: Genome sequencing provides tangible clinical benefit for individuals with idiopathic genetic disease, not only in the context of molecular genetic diagnosis of known rare conditions, but also in cases where prior clinical information regarding a new genetic disorder is lacking